iBio (IBIO) Total Current Liabilities (2011 - 2026)
iBio (IBIO) posted quarterly Total Current Liabilities of $6.5 million for Q1 2026, up 20.51% year-over-year from $5.4 million in Q1 2025, and up 10.22% quarter-over-quarter from $5.9 million in Q4 2025.
iBio (IBIO) Total Current Liabilities (2011 - 2026) Analysis & Trends
iBio (IBIO) has reported Total Current Liabilities for 16 consecutive years, with $6.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 20.51% year-over-year to $6.5 million; the TTM figure through Mar 2026 stood at $6.5 million (up 20.51% YoY), while the FY2025 annual figure was $6.1 million, up 59.01% from the prior year.
- Total Current Liabilities advanced to $6.5 million in Q1 2026 per IBIO's latest filing, from $5.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $32.2 million in Q3 2022 and bottomed at $3.5 million in Q3 2024.
- Historically, Total Current Liabilities has averaged $14.6 million across 5 years, with a median of $8.3 million in 2022.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 358.03% — and 2024, when it plunged 83.25%.
- iBio's Total Current Liabilities stood at $27.8 million in 2022, then slipped by 22.4% to $21.6 million in 2023, then slumped by 78.15% to $4.7 million in 2024, then climbed by 25.31% to $5.9 million in 2025, then rose by 10.22% to $6.5 million in 2026.
- Business Quant data shows IBIO's Total Current Liabilities at $6.5 million in Q1 2026, $5.9 million in Q4 2025, and $6.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 630.93 Mn |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | 6.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.50 Mn |
| Dec 31, 2025 | 5.90 Mn |
| Sep 30, 2025 | 6.05 Mn |
| Jun 30, 2025 | 6.11 Mn |
| Mar 31, 2025 | 5.40 Mn |
| Dec 31, 2024 | 4.71 Mn |
| Sep 30, 2024 | 3.47 Mn |
| Jun 30, 2024 | 3.84 Mn |
| Mar 31, 2024 | 21.43 Mn |
| Dec 31, 2023 | 21.55 Mn |
| Sep 30, 2023 | 20.71 Mn |
| Jun 30, 2023 | 22.11 Mn |
| Mar 31, 2023 | 22.28 Mn |
| Dec 31, 2022 | 27.78 Mn |
| Sep 30, 2022 | 32.20 Mn |
| Jun 30, 2022 | 30.44 Mn |
| Mar 31, 2022 | 8.28 Mn |
| Dec 31, 2021 | 8.35 Mn |
| Sep 30, 2021 | 8.10 Mn |
| Jun 30, 2021 | 6.65 Mn |